144 related articles for article (PubMed ID: 32215890)
1. Fibroblast Growth Factor 23 (FGF23) and Klotho Protein in Beta-Thalassemia.
Stefanopoulos D; Nasiri-Ansari N; Dontas I; Vryonidou A; Galanos A; Psaridi L; Fatouros IG; Mastorakos G; Papavassiliou AG; Kassi E; Tournis S
Horm Metab Res; 2020 Mar; 52(3):194-201. PubMed ID: 32215890
[TBL] [Abstract][Full Text] [Related]
2. Low serum iron is associated with high serum intact FGF23 in elderly men: The Swedish MrOS study.
Lewerin C; Ljunggren Ö; Nilsson-Ehle H; Karlsson MK; Herlitz H; Lorentzon M; Ohlsson C; Mellström D
Bone; 2017 May; 98():1-8. PubMed ID: 28212898
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and Klotho serum levels in healthy children.
Gkentzi D; Efthymiadou A; Kritikou D; Chrysis D
Bone; 2014 Sep; 66():8-14. PubMed ID: 24880094
[TBL] [Abstract][Full Text] [Related]
4. The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children.
Efthymiadou A; Kritikou D; Mantagos S; Chrysis D
Eur J Endocrinol; 2016 Apr; 174(4):473-9. PubMed ID: 26764419
[TBL] [Abstract][Full Text] [Related]
5. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
[TBL] [Abstract][Full Text] [Related]
6. Association of vitamin D and FGF23 with serum ferritin in hypoparathyroid thalassemia: a case control study.
Saki F; Salehifar A; Kassaee SR; Omrani GR
BMC Nephrol; 2020 Nov; 21(1):482. PubMed ID: 33198660
[TBL] [Abstract][Full Text] [Related]
7. Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation.
Mizia-Stec K; Wieczorek J; Polak M; Wybraniec MT; Woźniak-Skowerska I; Hoffmann A; Nowak S; Wikarek M; Wnuk-Wojnar A; Chudek J; Więcek A
Cytokine; 2018 Nov; 111():106-111. PubMed ID: 30138898
[TBL] [Abstract][Full Text] [Related]
8. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
[TBL] [Abstract][Full Text] [Related]
9. Phosphate control in reducing FGF23 levels in hemodialysis patients.
Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
[TBL] [Abstract][Full Text] [Related]
10. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
[TBL] [Abstract][Full Text] [Related]
11. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
Wolf M; Koch TA; Bregman DB
J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?
Bożentowicz-Wikarek M; Kocełak P; Owczarek A; Olszanecka-Glinianowicz M; Mossakowska M; Skalska A; Więcek A; Chudek J
Clin Biochem; 2015 Apr; 48(6):431-6. PubMed ID: 25583093
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and Klotho as cardiovascular risk factors in heart transplant recipients.
Przybylowski P; Wasilewski G; Janik L; Kozlowska S; Nowak E; Malyszko J
Transplant Proc; 2014 Oct; 46(8):2848-51. PubMed ID: 25380933
[TBL] [Abstract][Full Text] [Related]
14. FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients.
Malyszko J; Koc-Zorawska E; Matuszkiewicz-Rowinska J; Malyszko J
Transplant Proc; 2014 Oct; 46(8):2647-50. PubMed ID: 25380886
[TBL] [Abstract][Full Text] [Related]
15. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.
Imel EA; Peacock M; Gray AK; Padgett LR; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2011 Nov; 96(11):3541-9. PubMed ID: 21880793
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
[TBL] [Abstract][Full Text] [Related]
17. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
[TBL] [Abstract][Full Text] [Related]
19. Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children.
Kunert SK; Hartmann H; Haffner D; Leifheit-Nestler M
J Bone Miner Metab; 2017 Mar; 35(2):215-226. PubMed ID: 27017221
[TBL] [Abstract][Full Text] [Related]
20. Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women.
Imel EA; Liu Z; McQueen AK; Acton D; Acton A; Padgett LR; Peacock M; Econs MJ
Bone; 2016 May; 86():98-105. PubMed ID: 26965530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
